Look at the clients of PROT's new IR company!Access Pharmaceuticals, Inc. — OTC BB: ACCP
Asta Funding, Inc. — NASDAQ GS: ASFI
Baltek Corporation — (Bought out by Alcan)
InKine Pharmaceutical Company, Inc. — (Bought out by Salix Pharmaceuticals, Ltd., NASDAQ: SLXP)
NAPCO Security Technologies, Inc.— NASDAQ: NSSC
Norsat International, Inc.; TSX: NII AND OTC BB: NSATF
Savient Pharmaceuticals, Inc. — NASDAQ NM: SVNT
Simula Inc. — (Acquired by Armor Holdings)
Star Scientific, Inc. — NASDAQ: CIGX
Take-Two Interactive Software, Inc. — NASDAQ NM: TTWO
VISX, Inc. — (Bought out by Advanced Medical Optics (AMO) NYSE: EYE)
Proteonomix, Inc. (PROT) Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Agency
Press Release Source: Proteonomix On Monday June 7, 2010, 1:15 pm EDT
MOUNTAINSIDE, NJ--(Marketwire - 06/07/10) - Proteonomix, Inc. (Pinksheets:PROT - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced that it has retained Wolfe Axelrod Weinberger Associates LLC as its investor relations agency effective immediately.
Press Release Source: Proteonomix On Monday June 7, 2010, 1:15 pm EDT
MOUNTAINSIDE, NJ--(Marketwire - 06/07/10) - Proteonomix, Inc. (Pinksheets:PROT - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced that it has retained Wolfe Axelrod Weinberger Associates LLC as its investor relations agency effective immediately.
Michael Cohen, Chairman, President & CEO of Proteonomix, stated, "We've retained Wolfe Axelrod Weinberger Associates to assist us in communicating our unique strategy to the financial community to improve investor awareness. We believe an active investor relations program will broaden our investor exposure and we believe that Wolfe Axelrod Weinberger will provide us with seasoned experience in this area."
Wolfe Axelrod Weinberger Associates brings to its clients thirty years of successful investor relations experience and an extensive network of contacts. Wolfe Axelrod Weinberger Associates looks forward to working closely with Proteonomix, to accomplish its long-term objective of increasing shareholder value.
About Proteonomix, Inc.:Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromalCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromalCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit
No comments:
Post a Comment